(Q33787480)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Idarubicin including regimens in acute myelogenous leukemia in elderly patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Sica S

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Pagano L

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 September 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

59-68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

Acute myeloblastic leukaemia in the elderly

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Disappointments in treating acute leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

The treatment of acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Cardiovascular effects of doxorubicin (Adriamycin) and 4-demethoxydaunorubicin (Idarubicin) in the conscious rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Oral idarubicin in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

Bioavailability and pharmacology of oral idarubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900028-1

7 January 2021

10.1016/S1040-8428(99)00028-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586356%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference